Core Insights - The departure of Zhou Xiaping, the Senior Vice President and President of Greater China for Novo Nordisk, is set for March 31, marking a significant leadership change for the company in the region [1] - Zhou has been instrumental in doubling the revenue of Novo Nordisk's Greater China operations and improving its ranking in the Chinese pharmaceutical market by 8 positions [1][2] - The company has appointed Cai Yan as the new President of Greater China, who has over 23 years of experience with Novo Nordisk [2] Financial Performance - Novo Nordisk reported a global revenue of $34.5 billion for the first three quarters of 2025, reflecting a 15% year-on-year increase [2] - Revenue from the Chinese market reached $2.2 billion, with an 8% year-on-year growth, which is below the global average [2] - The core product, semaglutide, generated approximately $25.4 billion in sales, maintaining its position as the top-selling drug globally [2] Market Challenges - The growth momentum for Novo Nordisk is slowing, with a reported 11% decline in sales of semaglutide diabetes medications in China during the first half of the year [3] - The company has revised its annual performance expectations downward due to underperformance in key markets, including the U.S. [3] - Recent leadership changes include a significant global layoff plan affecting about 9,000 employees, approximately 11% of the total workforce [3]